Table 4.
Subgroup meta-analysis results of follow-up period.
| Outcomes | Subgroups | WMD (95% Cl) | P | Test for heterogeneity | Analysis model | Sample size | Number of study | ||
|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | P | Combination treatment | Tamsulosin monotherapy | ||||||
| TIPSS | ≤3 months | −1.680 (−2.729, −0.630) | 0.002 | 93.80% | 0.000 | R | 1,777 | 1,810 | 15 |
| >3 months | −1.330 (−3.485, 0.825) | 0.227 | 85.10% | 0.009 | R | 93 | 87 | 2 | |
| SIPSS | ≤3 months | −0.276 (−0.625, 0.073) | 0.121 | 73.50% | 0.000 | R | 998 | 995 | 7 |
| VIPSS | ≤3 months | −0.311 (−0.655, 0.033) | 0.076 | 43.40% | 0.048 | F | 1,051 | 1,048 | 8 |
| QMAX | ≤3 months | 1.799 (0.719, 2.878) | 0.001 | 94.20% | 0.000 | R | 959 | 894 | 11 |
| >3 months | 1.973 (3.571, 0.376) | 0.015 | 0.00% | 0.524 | F | 93 | 87 | 2 | |
| OABSS | ≤3 months | −1.202 (−2.044, −0.361) | 0.005 | 95.60% | 0.000 | R | 613 | 647 | 7 |
| QOL | ≤3 months | −0.382 (−0.746, −0.018) | 0.039 | 94.50% | 0.000 | R | 903 | 905 | 9 |
| PVR | ≤3 months | 3.138 (−2.011, 8.286) | 0.232 | 78.30% | 0.000 | R | 964 | 961 | 7 |
| >3 months | −9.439 (−18.161, −0.717) | 0.034 | 77.30% | 0.036 | R | 93 | 87 | 2 | |
| Urgency episodes per 24 h | ≤3 months | 0.208 (0.086, 0.330) | 0.001 | 23.20% | 0.237 | F | 1,093 | 996 | 4 |
| >3 months | −0.094 (−0.305, 0.116) | 0.378 | 0.00% | 0.351 | F | 93 | 87 | 2 | |
| Micturitions per 24 h | ≤3 months | 0.145 (−0.156, 0.445) | 0.345 | 56.30% | 0.019 | R | 1,006 | 996 | 5 |
| PSA | ≤3 months | 0.192 (0.132, 0.253) | <0.001 | 0.00% | 0.596 | F | 667 | 689 | 6 |
WMD, Weighted mean difference; CI, confidence interval; R, random effects model; F, fixed effects model; TIPSS, Total International Prostate Symptom Score; SIPSS, Storage International Prostate Symptom Score; VIPSS, Voiding International Prostate Symptom Score; QOL, Quality of life; QMAX, Maximal urinary flow rate; PVR, Post void residual volume; PSA, Prostate specific antigen; OABSS, Overactive bladder symptom score.
Bold values meant P-value < 0.05.